

**FOR IMMEDIATE RELEASE**

**Contact: Andrew Krouse**  
(434) 974-6969  
krouse@tautherapeutics.com  
[www.tautherapeutics.com](http://www.tautherapeutics.com)

**Dr. Daniel Von Hoff and Mr. John McCray to Join Tau Therapeutics**  
*Company Adds Clinical Development and Business Development Expertise for Platform Expansion*

(Charlottesville, VA – May 1, 2014) [Tau Therapeutics LLC](http://www.tautherapeutics.com) announced two key hires for its executive management team. Daniel D. Von Hoff, M.D., F.A.C.P., will advise Tau on clinical development strategy for its platform of T-type calcium channel inhibitors, including its novel [Interlaced Therapy™](#) approach. John McCray, M.B.A, will fill the new position of Chief Business Officer. Both will contribute to the company’s goal of developing and commercializing T-type calcium channel inhibitors for treating solid tumors.

Dr. Von Hoff is a recognized expert in clinical trial design, particularly in oncology. He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA's Oncology Advisory Committee. Von Hoff is a past president of the American Association for Cancer Research (AACR), was on the AACR and the American Society of Clinical Oncology (ASCO) Board of Directors, and is a fellow of the American College of Physicians. ASCO recently named Dr. Von Hoff one of 50 Oncology Luminaries, celebrating doctors who over the past half-century have significantly advanced cancer care.

Dr. Von Hoff has been integral to the development of multiple anticancer agents, including such routinely used agents as mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib. He is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute, and Clinical Professor of Medicine at the University of Arizona.

“We are proud that a key opinion leader of Dr. Von Hoff’s stature will join us in introducing a new class of oncology drugs that control the cell cycle by selectively inhibiting the T-type calcium channel. We believe his expertise across multiple oncology indications will enable us to launch clinical trials in several solid tumor cancers, including breast, ovary and lung cancers,” said Andrew J. Krouse, President and CEO of Tau Therapeutics.

Mr. McCray brings over 25 years’ experience in large and small pharmaceutical companies, including operations, financial, business development, legal, marketing and public policy. He has managed financings in both public and emerging private companies. Before serving as Chief Operating Officer at Molecular Insight

Pharmaceuticals and Pan Pacific Pharmaceuticals, he was Vice President of Marketing at Sepracor, where he led the successful launch of that company's first product.

"I look forward to working closely with Mr. McCray and will rely on his broad knowledge of business development to secure the partnerships and funding required to commercialize our platform," said Andrew Krouse.

### **About Tau Therapeutics LLC**

Tau Therapeutics is a clinical stage, private biotechnology company ushering in a new class of oncology drugs for solid tumors. From its drug discovery platform, Tau is developing new chemical entities that control the cell cycle by selectively inhibiting the T-type calcium channel – Cav3. Tau's proprietary knowledge of Cav3 calcium channels and its ability to develop tailored T-type calcium channel blockers offer a non-toxic and potentially indispensable addition to the emerging chemotherapy cocktails.

Tau's lead drug is a T-type calcium channel blocker, mibefradil, a molecule with a well-known safety profile that was formerly used for treating hypertension. Tau is clinically assessing this drug in solid tumors as a proof of concept for the role of Cav3 in cancer treatment and has also developed a unique protocol – Interlaced Therapy, which is poised to overcome drug resistance and amplify the effects of conventional cancer therapies. A single site Phase 1 dose-finding study in healthy volunteers was completed in December 2012. Tau is also conducting a multi-site NCI Adult Brain Tumor Consortium-sponsored [Phase 1b clinical trial](#) in brain cancer.

### **Forward-Looking Statement**

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.